BONE BIOLOGICS CORP (BBLG)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.32-6.74%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · BBLG
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Consistent with the outlook provided in January, the Company expects to complete patient enrollment in the study by year-end and may provide interim updates as appropriate.
Stated in a supplied disclosure. Management reported: “Consistent with the outlook provided in January, the Company expects to complete patient enrollment in the study by year-end and may provide interim updates as appropriate.” “Advancing the NB1 clinical program The Company continues to advance its first-in-human pilot clinical study of NB1, which combines the recombinant human NELL-1 protein (rhNELL-1) with demineralized bone matrix for use in spinal fusion procedures.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The Company believes this financing extends its operating runway through Q2 2027, providing the capital base to execute the clinical and operational priorities set out at the start of the year withou…
Stated in a supplied disclosure. Management reported: “The Company believes this financing extends its operating runway through Q2 2027, providing the capital base to execute the clinical and operational priorities set out at the start of the year without near-term reliance on additional financing.” “Strengthened capital position and extended runway In July 2026, the Company completed a private placement with a single healthcare-focused institutional investor, priced at-the-market under Nasdaq rules, generating gross proceeds of approximately $3.0 million before deducting placement agent fees and offering expenses.”
Product stability and manufacturing readiness In May 2026, the Company announced that the validated shelf life of its rhNELL-1 protein had been extended to 29 months, building on the 24-month milesto…
Stated in a supplied disclosure. Management reported: “Product stability and manufacturing readiness In May 2026, the Company announced that the validated shelf life of its rhNELL-1 protein had been extended to 29 months, building on the 24-month milestone achieved in December 2025.” “The Company believes the extended stability profile supports manufacturing flexibility, lot sizing and supply chain planning as the program progresses toward a potential future pivotal study.”
Add additional hospital sites in Australia and complete enrollment in the NB1 pilot study by year-end 2026.
Control operating losses and cash flow burn while advancing clinical and operational programs.
Over the trailing year it converted 1.20x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.